Avendus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -25.46%
- Profit Growth -1176.07%
- Ebitda -729.92%
- Net Worth -119.16%
- Total Assets 0.89%
About Avendus Pharmaceuticals
Avendus Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 July 2014 and has a history of Ten years and seven months. Its registered office is in Nashik, Maharashtra, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Shainesh Pullani, Sandesh Gujarathi, and Siddharth Shah serve as directors at the Company.
Company Details
-
Location
Nashik, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74900MH2014PTC255818
-
Company No.
255818
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
03 Jul 2014
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Avendus Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shainesh Pullani
|
Director | 03-Jul-2014 | Current |
|
Sandesh Gujarathi
|
Director | 03-Jul-2014 | Current |
|
Siddharth Shah
|
Director | 03-Jul-2014 | Current |
Financial Performance of Avendus Pharmaceuticals.
Avendus Pharmaceuticals Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 25.46% decrease. The company also saw a substantial fall in profitability, with a 1176.07% decrease in profit. The company's net worth observed a substantial decline by a decrease of 119.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Avendus Pharmaceuticals?
In 2017, Avendus Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Avendus Pharmaceuticals?
Unlock and access historical data on people associated with Avendus Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Avendus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Avendus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.